Charles N. York II - Feb 15, 2024 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
COO, CFO AND SECRETARY
Signature
/s/ Charles N. York II
Stock symbol
DAWN
Transactions as of
Feb 15, 2024
Transactions value $
-$40,651
Form type
4
Date filed
2/20/2024, 06:36 PM
Previous filing
Jan 9, 2024
Next filing
May 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Options Exercise +1.38K +0.51% 272K Feb 15, 2024 Direct F1
transaction DAWN Common Stock Options Exercise +2.25K +0.83% 274K Feb 15, 2024 Direct F1
transaction DAWN Common Stock Options Exercise +6.63K +2.42% 280K Feb 15, 2024 Direct F1
transaction DAWN Common Stock Sale -$40.7K -2.67K -0.95% $15.25 278K Feb 16, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DAWN Restricted Stock Unit (RSU) Options Exercise $0 -1.38K -12.5% $0.00 9.63K Feb 15, 2024 Common Stock 1.38K Direct F1, F3
transaction DAWN Restricted Stock Unit (RSU) Options Exercise $0 -2.25K -8.33% $0.00 24.8K Feb 15, 2024 Common Stock 2.25K Direct F1, F3
transaction DAWN Restricted Stock Unit (RSU) Options Exercise $0 -6.63K -6.25% $0.00 99.4K Feb 15, 2024 Common Stock 6.63K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F2 The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs.
F3 The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.